Skip to main content
Publications
Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Bommireddy R, Pack CD, Bozeman EN, Patel JM, Vartebedian VF, Munoz LE, Shafizadeh Y, Menon AP, Lakshmanan R, Reddy SJC, Selvaraj P. Membrane-based immunotherapy with immune checkpoint blockade antibodies confers protection against metastatic breast cancer. Poster presented at the Immunology 2017 Meeting; May 12, 2017. Washington, DC. [abstract] J Immunol. 2017 May 1; 198(1_Supplement):120.8. doi: 10.4049/jimmunol.198.Supp.120.8
Munoz LE, Bommireddy R, Margaroli C, Shafizadeh Y, Bozeman EN, Menon AP, Kumar J, Lakshmanan R, Selvaraj P. HER-2+ breast cancer cells expressing GPI-anchored cytokines induce long lasting antitumor memory response. Poster presented at the Immunology 2017 Meeting; May 12, 2017. Washington, DC. [abstract] J Immunol. 2017 May 1; 198(1_Supplement):79.28. Previously presented at the International Congress of Immunology (ICI) 2016. doi: 10.4049/jimmunol.198.Supp.79.28
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Den Berg DV, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Kjaer SK, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah HDP, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock S, Sherman M, Garcia-Closas M. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009 Mar;69(6):2349-57.